Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.
The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs - $8.19 billion - and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.
Key Market for the Future
Visiongain predicts that the retail market for diabetes medications will continue to show significant growth for what is an already large market. Actos from Takeda is the leading oral anti-diabetic product and appears set to retain this status. However, it is co-marketed with Eli Lilly which has new products to make available. Lantus from Sanofi-Aventis is the leading insulin product. But there are three new products available, including the world's first inhaled insulin product Exubera from Pfizer.
Why you should buy this report:
Diabetes treatment is a leading therapeutic area and is about to become even more important.
The world's first inhaled insulin product has just been approved to the world's largest pharmaceutical company. This report will help you to assess just what impact that this is likely to have.
The market is dominated by a Japanese product is this a sign of things to come from a previously struggling side of the industry?
Visiongain has taken the latest available financial statistics and forecast revenue figures for all the leading products.
The report contains analysis of the pipeline and potential blockbuster products of the next five years.
Table of Contents
1. Executive Summary
1.1 The Global Diabetes Market Will Exceed $21 Billion by 2011
1.2 Aims, Scope and Format of the Report
1.3 Research Methodology
2. Introduction: A Background to Diabetes
2.1 Diabetes and Insulin
2.2 The Biology of Diabetes Mellitus
2.3 Metabolic Syndrome and Its Relationship to Diabetes
2.4 Type 1 Diabetes Described
2.5 Causes of Type 1 Diabetes 2.5.1 Auto-immune Response 2.5.2 Genetic Abnormalities 2.5.3 Viruses 2.5.4 Cow’s Milk
2.6 Symptoms of Type 1 Diabetes 2.6.1 Hypoglycemia 2.6.2 Ketoacidosis
2.7 Type 2 Diabetes Described
2.8 Causes of Type 2 Diabetes 2.8.1 Insulin Resistance 2.8.2 Genetic Factors
2.9 Symptoms of Type 2 Diabetes
2.10 Gestational Diabetes
2.11 Maturity-onset Diabetes in Youth
2.12 Secondary Diabetes
2.13 Diagnosing Diabetes
2.14 New Diagnostic Guidelines
2.15 Pre-diabetes
2.16 Further Health Consequences of Diabetes 2.16.1 Cardiovascular Disease 2.16.2 Kidney Disease 2.16.3 Blindness 2.16.4 Nervous System Disease and Amputations 2.16.5 Dental Disease 2.16.6 Impotence 2.16.7 Complications in Pregnancy
2.17 Diabetes Tests 2.17.1 Fasting Plasma Glucose (FPG) Test 2.17.2 Glucose Tolerance Test 2.17.3 Test for Glycosylated Haemoglobin 2.17.4 Fructosamine
2.18 Specific Goals of DiabetesTreatment 2.18.1 Benefits of Improved Blood Sugar Control
2.19 Diabetes Risk Factors 2.19.1 Type 1 Diabetes Risk Factors 2.19.2 Type 2 Diabetes Risk Factors 2.19.3 Age of 40 Years or Older 2.19.4 Obesity and Physical Inactivity 2.19.5 Family History of Diabetes 2.19.6 Diabetes During Pregnancy 2.19.7 Ethnicity 2.19.8 Low Birth Weight
2.20 Diabetes Prevalence Will Increase to 370m by 2030
4.3 The Treatment of type 2 Diabetes by Lifestyle Measures 4.3.1 Diet and Weight Loss 4.3.2 Exercise 4.3.3 Monitoring Blood Glucose 4.3.4 Daily Foot Care
5. The World Diabetes Market, 2005-2011
5.1 Growth Rates in the World Diabetes Market Will Increase in 2007 due to Exubera
5.2 Oral Anti-diabetics Dominate the World Diabetes Market
5.3 Thiazolidinediones Are the Leading Oral Anti-diabetic Drugs
5.4 Takeda Leads the World's Diabetes Market With Actos
5.5 The Price of Insulins and Oral Anti-diabetic Drugs 5.5.1 Exbuera Will Be More Expensive Than Other Insulins
6. The World Thiazolidinediones Market, 2005-2011
6.1 GSK and Takeda Compete for Dominance in the Thiazolidinedione Market
7. The World Sulphyonlyureas Market, 2005-2011
7.1 Sulphyonlyureas Are the Second Most Popular Drug Class in the World Oral Anti-diabetics Market
7.2 Amaryl Dominates the Sulphyonlyurea Class But Will See Declining Revenues Due to Patent Loss
8. The World Biguanides Market, 2005-2011
8.1 Glucophage Will Continue to Earn High Revenues Despite Patent Loss
8.2 Glucophage: A lesson in Life-Cycle Management
9. The World PGR Market, 2005-2011
9.1 Starlix and NovoNorm: A History
10. The World AGI Market, 2005-2011
10.1 The AGI Market Will Show Negative Growth at the End of the Forecast Period
11. The World IM and PPARs Market: New Classes of Oral Anti-diabetics
11.1 Incretin Mimetic
11.2 PPAR
11.3 Byetta Will Earn Blockbuster Revenues by 2011
11.4 Pargluva Will Initially Earn Only Small Revenues After Its Potential Launch in 2010
12. The World Diabetes Market by Country, 2005
12.1 The US Takes Over 55% of the World Diabetes Market
12.2 Oral Anti-diabetic Drugs Generate Higher Revenues than the Insulins
12.3 In the US Nearly 70% of All Diabetic Revenues Come from Anti-diabetic Drugs
12.4 Generics in the US Take Nearly 20% of the Market for Oral Anti-diabetics
12.5 In 2004 Lantus Was the Biggest Selling Individual Insulin Product in the US Market
12.6 The Japanese Oral Anti-diabetic Market Shows Low Growth
12.7 The Japanese Insulin Market Is Dominated by Novo Nordisk
13. The World Insulins Market, 2005-2011
13.1 The World Insulin Market Will Be Worth Over $11bn By 2011
14. Pipeline for Diabetic Treatments
14.1 Unmet Needs for Diabetes Treatments
14.2 Leading Pipeline Products for the Diabetes Market
14.3 Other Agents in Development for Treating Diabetes 14.3.1 Agents in Phase III of Clinical Development 14.3.2 Agents That Have Completed Phase III of Clinical Development 14.3.3 Other Agents For Which Final Regulatory Approval Is Pending
14.4 Other Experimental Studies: Can Immunosuppressant Drugs and Insulin Treatments Suppress Development of Type 1 Diabetes?
15. Insulin Delivery Technologies
15.4 Insulin Jet Injectors
15.5 External Insulin Pumps
16. Promising New Technology for the Treatment of Type 1 Diabetes
16.1 Implantable Insulin Pumps
16.2 Insulin Pills
16.3 Transdermal Insulin
16.4 Oral Spray Insulin
16.5 Organ Transplantation
17. An Analysis of Factors That Influence the Diabetes Market: A SWOT Analysis
17.1 SWOT Analysis of the Diabetes Market
17.2 An Expanding Patient Population Is the Principal Driver in the Diabetes Market
17.3 The Diabetes Market Has Opportunities for Continuing Growth
17.4 Advances in Technology Are Likely to Bring Benefits to the Market
17.5 Generics Pose the Most Significant Threat to the World Diabetes Market
17.6 Generics are the Largest Threat to the Branded Diabetes Market
17.7 What Unmet Market Needs Exist in the Diabetes Market? - Experts Provide Their Views
17.8 Important Patient Sub-populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
17.9 Improvements in Transplantation Success and Stem Cell Research will Reduce the Market for Insulin
18. Conclusion - Diabetes Is a Growing Market in Both Developed and Developing Countries
Appendix A: About visiongain
List of Tables
Table 2.1 Main Insulin Products Mentioned in the Report by Company, 2006
Table 2.2 Main Oral Anti-diabetic Products Mentioned in the Report by Company With US Patent Expiry Dates, 2006
Table 2.3 Diagnosis by the Fasting Plasma Glucose Test
Table 2.4 Top Ten Countries for Highest Estimated Cases of Diabetes, 2000 and 2030
Table 2.5 Leading Causes of Death in the US, 2002
Table 3.1 Types of Insulin
Table 4.1 Oral Anti-diabetic Drugs Currently Available
Table 5.1 Forecast Revenue ($m) and Growth Rate (%) for Insulin and Oral Anti-diabetics, 2004-2011
Table 5.2 Market Share of Insulin and Oral Anti-diabetics, 2005
Table 5.3 Market Share of Insulin and Oral Anti-diabetics, 2011
Table 5.4 Forecast Revenue ($m) and Growth Rate (%) for the Classes of Oral Anti-diabetics, 2004-2011
Table 5.5 Market Share of Insulin and Oral Anti-diabetics, 2005
Table 5.6 Market Share of Insulin and Oral Anti-diabetics, 2011
Table 5.7 Company Market Share (%), Insulin and Oral Anti-diabetic Drugs, 2005
Table 5.8 Company Market Share (%), Insulin and Oral Anti-diabetic Drugs, 2011
Table 5.9 Drug Prices ($) For Insulin and Oral Anti-diabetics, 2006
Table 6.1 Forecast Revenue ($m) and Growth Rate (%) for Insulin and Oral Anti-diabetics, 2004-2011
Table 6.2 Company Market Share (%) for the Thiazolidinedione Class, 2005 and 2011
Table 7.1 Table 7.1 Forecast Revenue ($m) and Growth Rate (%) for the Sulphonylureas, 2004-2011
Table 8.1 Forecast Revenue ($m) and Growth Rate (%) for the Biguanides, 2004-2011
Table 9.1 Forecast Revenue ($m) and Growth Rate (%) for the PGRs, 2004-2011
Table 10.1 Forecast Revenue ($m) and Growth Rate (%) for the AGIs, 2004-2011
Table 11.1 Forecast Revenue ($m) and Growth Rate (%) for the Incretin Mimetic Class, 2004-2011
Table 12.1 Total Diabetes Revenues (Oral and Insulins Combined) ($m) by Country, 2004
Table 12.2 Total Insulin Revenues ($m) by Country, 2004
Table 12.3 Total (Branded Only) Oral Anti-diabetic Drug Revenue ($m) by Country, 2004
Table 12.4 Market Share (%) for Insulins and Oral Anti-diabetic Drugs by Country, 2004
Table 12.5 Ratio of Insulin/Oral Use by Revenue (as %) Per Country, 2004
Table 12.6 US Revenues ($m) for Branded and Generic Oral Anti-diabetics, 2004
Table 12.7 Insulin Revenues ($m) From The US Market, 2004
Table 12.8 Company Revenue ($m) and Market Share (%) for Insulins on the US Market, 2004
Table 12.9 Japan Oral Anti-diabetic Market, 2004
Table 12.10 Japanese Oral Anti-diabetic Market Share (%) by Company, 2004
Table 12.11 Japanese Insulin Market ($m), 2005
Table 12.12 Japanese Insulin Market Share (%) by Company, 2004
Table 12.13 Revenues ($m) For The European Oral Anti- diabetic Market, 2004
Table 12.14 Market Share (%) for Branded and Generic Oral Anti-diabetic Drugs by European Country, 2004
Table 12.15 Revenues ($m) For The European Oral Anti- diabetic Market, 2004
Table 12.16 Revenues ($m) For The European Insulin Market, 2004
Table 12.17 Company Market Share (%) For Insulin Products for the European Market, 2004
Table 12.18 Diabetes Market Revenues ($m) for India and China, 2004
Table 12.19 Market Share (%) For Oral Anti-diabetics and Insulin For India and China, 2004
Table 13.1 Forecast Revenue ($m) and Growth Rate (%) of the World Insulin Market, 2004-2011
Table 13.2 Company Market Share (%) of the World Insulin Market, 2005
Table 13.3 Major Insulin Products by Company, 2006
Table 13.4 Company Market Share (%) of the World Insulin Market, 2011
Table 14.1 Leading Pipeline Products, 2005/6
Table 14.2 Agents for Diabetes in Phase III of Clinical Development
Table 14.3 Agents for Diabetes that Have Completed Phase III of Clinical Development
Table 14.4 Agents for Diabetes for Which Final Regulatory Approval Is Pending
Table 14.5 Other Agents in Clinical Development, by Country
Table 15.1 Syringes for Administering Insulin
Table 15.2 Insulin Pens Available in the US, 2006
Table 15.3 US Aids for Injection, 2006
Table 15.4 Types of US Insulin Jet Injectors, 2006
Table 15.5 US External Insulin Pumps, 2006
Table 17.1 Patent Expiration of the Leading Diabetes Treatments, 2006
List of Figures
Figure 5.1 Forecast Revenue ($m) for Insulin and Oral Anti-diabetics, 2004-2011
Figure 5.2 Growth Rates of World Diabetes Market ($bn), 2004-2011
Figure 5.3 Revenues ($bn) for Insulin and Oral Anti-diabetics, 2004-2011
Figure 5.4 Revenues ($bn) for Insulin and Oral Anti-diabetics, 2004-2011
Figure 5.5 Growth Rates (%) for Insulin and Oral Anti- diabetics, 2004-2011
Figure 5.6 Market Share (%) for Insulin and Oral Anti-diabetics, 2005
Figure 5.7 Market Share (%) for Insulin and Oral Anti-diabetics, 2011
Figure 5.8a Forecast Revenue ($m) for the Classes of All Oral Anti-diabetics, 2004-2011
Figure 5.8b Forecast Revenue ($m) for the Classes of Oral Anti-diabetics But Not Including the Thiazolidiones, 2004-2011
Figure 5.9 Market Share (%) for Oral Anti-diabetics, 2005
Figure 5.10 Market Share (%) for Oral Anti-diabetics, 2011
Figure 5.11 Company Market Share Insulin and Oral Anti- diabetic Drugs, 2005
Figure 5.12 Company Market Share Insulin and Oral Anti-diabetic Drugs, 2011
Figure 6.1 Forecast Revenue ($m) for the Thiazolidinedione Class of Oral Anti-diabetics, 2004-2011
Figure 6.2 Market Share (%) of the Thiazolidinediones, 2005
Figure 6.3 Market Share (%) of the Thiazolidinediones, 2011
Figure 7.1 Forecast Revenue ($m) for the Sulphonylurea Class of Oral Anti-diabetics, 2004-2011
Figure 7.2 Market Share (%) of the Sulphonylureas, 2005
Figure 7.3 Market Share (%) of the Sulphonylureas, 2011
Figure 8.1 Forecast Revenue ($m) the Biguanide Class of Oral Anti-diabetics, 2004-2011
Figure 9.1 Forecast Revenue ($m) the PGRs Class of Oral Anti-diabetics, 2004-2011
Figure 9.2 Market Share (%) of the PGRs, 2005
Figure 9.3 Market Share (%) of the PGRs, 2011
Figure 10.1 Forecast Revenue ($m) for the AGIs Class of Oral Anti-diabetics, 2004-2011
Figure 10.2 Market Share (%) of the AGIs, 2005
Figure 10.3 Market Share (%) of the AGIs, 2011
Figure 11.1 Forecast Revenue ($m) the Incretin Mimetic Class of Oral Anti-diabetics, 2004-2011
Figure 12.1 Total Diabetes Revenues (Oral and Insulins Combined) ($m) by Country, 2004
Figure 12.2 Total Insulin Market Share (%) by Country, 2004
Figure 12.3 Total (Branded Only) Oral Anti-diabetic Market Share (%) by Country, 2004
Figure 12.4 Market Share (%) for Insulins and Oral Anti-diabetic Drugs by Country, 2004
Figure 12.5 Ratio of Insulin/Oral Anti-diabetic by Revenue (as %) by Country
Figure 12.6 Market Share (%) for Branded and Generic Oral Anti-diabetics, 2004
Figure 12.7 Company Market Share (%) for Insulins on the US Market, 2004
Figure 12.8 Company Market Share (%) for Insulins on the Japanese Market, 2004
Figure 12.9 Market Share (%) For Branded and Generic Diabetes Drugs In The Leading EU Markets, 2004
Figure 12.10 Revenue ($m) of Leading Insulin Products in European Market, 2004
Figure 12.11 Company Market Share (%) For Insulin Products For the European Market, 2004
Figure 13.1 Forecast Revenues ($m) for the World Insulin Market, 2005-2011
Figure 13.2 Company Market Share (%) of the World Insulin Market, 2005
Figure 13.3 Company Market Share (%) of the World Insulin Market, 2011
Figure 13.3 Forecast Revenues ($m), For the Leading Insulin Products, 2004-2011
Figure 13.5 Company Market Share (%) of the Insulin Market, 2011
Figure 14.1 Patient Preference for Exubera Insulin
Figure 15.1 Locations for Injecting Insulin
Figure 17.1 SWOT Chart for the Diabetes Market, 2005-2011
Figure 18.1 The World Diabetes Market by Revenue ($m), 2004-2011
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
